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Abstract
Background: The natural history of HSV-2 infection and role of HSV-2 reactivations in HIV disease progression are unclear.
Methods: Clinical symptoms of active HSV-2 infection were used to classify 1,938 HIV/HSV-2 co-infected participants of the
Women’s Interagency HIV Study (WIHS) into groups of varying degree of HSV-2 clinical activity. Differences in plasma HIV
RNA and CD4+ T cell counts between groups were explored longitudinally across three study visits and cross-sectionally at
the last study visit.
Results: A dose dependent association between markers of HIV disease progression and degree of HSV-2 clinical activity
was observed. In multivariate analyses after adjusting for baseline CD4+ T cell levels, active HSV-2 infection with frequent
symptomatic reactivations was associated with 21% to 32% increase in the probability of detectable plasma HIV RNA (trend
p= 0.004), an average of 0.27 to 0.29 log10 copies/ml higher plasma HIV RNA on a continuous scale (trend p,0.001) and 51
to 101 reduced CD4+ T cells/mm3 over time compared to asymptomatic HSV-2 infection (trend p,0.001).
Conclusions: HIV induced CD4+ T cell loss was associated with frequent symptomatic HSV-2 reactivations. However, effect
of HSV-2 reactivations on HIV disease progression markers in this population was modest and appears to be dependent on
the frequency and severity of reactivations. Further studies will be necessary to determine whether HSV-2 reactivations
contribute to acceleration of HIV disease progression.
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Introduction
Individuals with human immunodeficiency virus (HIV) infection
are often found to be co-infected with herpes simplex virus type 2
(HSV-2) – the causative agent of genital herpes (GH).
Genital herpes has a widely variable clinical course. Some
individuals manifest severe forms of disease with the frequent
development of painful and typical mucocutaneous lesions while
others experience mild or atypical forms with manifestations that
can easily go unnoticed [1]. In rare situations, the herpes virus can
disseminate systemically and cause devastating complications in
many internal organs [2–4]. The effect of this clinical heteroge-
neity on the course of HIV is not clear.
The nature and precise mechanisms of interaction between
these two sexually transmitted pathogens are still incompletely
understood with studies often producing conflicting results leading
to ongoing debate on whether HSV-2 is indeed a significant risk
factor for HIV acquisition, transmission or disease progression.
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Some experts argue that there is sufficient evidence of viral synergy
between these two sexually transmitted pathogens to call for
immediate actions to control HSV-2 [5]. Others argue that recent
trials demonstrating no effect of HSV suppressive therapy on HIV
acquisition and transmission [6–8] suggest that HSV-2 based
interventions will have little to no effect on HIV epidemic [9].
We attempted to investigate this interaction within Women’s
Interagency HIV Study (WIHS), the nation’s largest cohort study
of HIV natural history by evaluating the association of the type
(symptomatic vs. asymptomatic) and severity (frequency of
symptomatic recurrences) of HSV-2 infection with HIV disease
progression markers (plasma HIV RNA and CD4+ T cell count)
among highly active antiretroviral therapy (HAART) naı¨ve HIV/
HSV-2 co-infected participants of WIHS.
Methods
Ethics Statement
This study was conducted under IRB approval of WIHS Data
Management and Analysis Center (Principal Investigator –
Stephen Gange). IRB number: H.34.97.05.19.A2. Written
informed consent was obtained from all participants.
Study population
The study population consisted of 2,056 HIV infected
participants recruited into WIHS between 1994 and 1995. WIHS
is an ongoing multicenter cohort study of HIV natural history in
women across six sites in the U.S. (Los Angeles, CA; Washington,
DC; the San Francisco Bay area, CA; New York City/Bronx, NY;
Brooklyn, NY; and Chicago, IL). Complete physical and
gynecological examination with collection of biologic specimens
was done on women semiannually since 1994. Gynecological
examination included assessment for genital tract infections,
including ulcers and intraepithelial dysplasia as previously
described [10]. Detailed review of the WIHS study population
and methods have been previously published [11].
Study follow up
Study follow up was restricted to the first three WIHS visits (1.5
years of follow up). Less than 3% of participants were treated with
HAART during that time period. To avoid possible selection and
survival biases participants with only one (n = 221) or two (n = 237)
study visits as well as those on HAART (n = 40) were excluded.
Exposure assessment
1) Laboratory assessment of HSV serostatus. Serologic
reactivity to HSV-1 and HSV-2 was determined by a
commercially available type-specific glycoprotein G-based
enzyme immunoassay (gG-EIA, Gull Laboratories, Salt Lake
City, Utah, USA) at enrollment as previously described [12,13].
Negative and equivocal results were confirmed by Western Blot as
previously described [13–15]. The sensitivity of the gG-EIA for
HSV-1 is 95% and the specificity is 96%. For HSV-2, the
sensitivity is 98% and the specificity is 97% [12,13].
2) Clinical assessment of HSV-2 infection and
classification of study groups. Clinicians’ assessment of
genital herpes was based on visualization of ulcers and/or vesicles
in the genital area during pelvic exam. Clinicians were either
women’s health nurse practitioners or physician gynecologists. All
have been trained to complete the WIHS protocol. An interval
history of genital sores was collected by self-report at each study
visit. Participants were classified into groups based on the type of
HSV-2 infection (symptomatic or asymptomatic) and frequency of
visits with genital lesions observed over the duration of the initial
three visits. This classification was based on the assumption that the
likelihood of having active and more severe HSV-2 infection will be
highest in clinically symptomatic women presenting with herpetic
lesions at least once during the specified study period as opposed to
women who remain clinically asymptomatic during the same time
period. This assumption also stems from the results of preliminary
work in which the presence and quantity of HSV-2 DNA in lower
genital tract was highest in symptomatic women presenting with
typical herpetic lesions (,30%) compared to women clinically
asymptomatic over extended periods of time or women with other
lesions (,10%) when cervicovaginal lavage samples from a subset of
WIHS women (n,400) were tested by polymerase chain reaction
(Aumakhan, unpublished thesis). Based on this assumption and
data, a participant who was HSV-2 seropositive but negative for
potential indicators of active HSV-2 infection, such as presence of
any genital lesions and negative for a history of genital sores over the
duration of this study was considered as having asymptomatic HSV-
2 infection and considered as having symptomatic HSV-2 infection
if she had at least one visit (out of three) at which she presented with
genital lesions identified by clinicians as herpetic and/or had a
positive history of GH sores in between the visits. The degree of
HSV-2 clinical activity among symptomatic women was then
graded from: a) mild symptomatic (only self report positive but no
lesions at any study visit), b) mild to moderate (lesions at only one of
the study visits), c) moderate (lesions at two visits), and d) severe
symptomatic (lesions at all three study visits). Women with lesions
not identified as herpetic and negative for a history of genital sores
were considered as having symptoms not highly suggestive of active
HSV-2 infection and thus, excluded.
Outcome assessment
HIV RNA plasma load was quantified by an isothermal nucleic
acid sequence-based amplification assay (NASBA/Nuclisens,
Merieux, Durham, North Carolina, USA), which had a lower
limit of quantification (LOQ) of 4,000 copies/ml. CD4+ T cells
were quantified using standard flow cytometry methods.
Statistical analysis
Plasma HIV RNA load was stratified into two categories with
the cutpoint at the LOQ: #4,000 and .4,000. HIV RNA values
below the LOQ were summarized using proportions, and values
above the LOQ were log10 transformed for comparison purposes.
Univariate analyses were carried out comparing selected charac-
teristics between defined study groups. Proportions were com-
pared using the chi square test. Continuous variables were
summarized with medians and compared using the Wilcoxon
rank-sum (Mann-Whitney) test. The Generalized Estimating
Equations (GEE) method with robust variance estimation was
used to explore the mean differences in plasma HIV RNA and
CD4+ T cell counts between the study groups. To explore the
cumulative association of repeated HSV-2 episodes on HIV
markers, linear regression for continuous and Poisson extensions of
log binomial models [16] for dichotomous outcomes were
implemented at the third or last follow up visit. Multivariate
models adjusted for selected demographic and risk variables
known to be associated with HIV risk and disease progression as
well as variables that were statistically different in crude
comparisons and included age, race, injection and noninjection
drug use, number of lifetime sexual partners, use of herpes
medications and antiretroviral therapy, as well as baseline CD4+
T cell count. The asymptomatic group was the reference group in
all models. Analyses were carried out with STATA, version 10
(Stata Corporation, College Station, Texas, USA). Statistical
significance was defined as a p-value of ,0.05.
HSV-2 Reactivations and HIV
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Results
a) Study groups
Ninety four percent of the source cohort (n = 1,938) had known
baseline HSV-2 serostatus and of those 78% (n = 1,510) were
HSV-2 seropositive (Figure 1). After excluding women with
incomplete follow up as well as those on HAART there were
1,012 women eligible for the study. Of 1,012 women, 262
(n = 26%) were classified as asymptomatic for HSV-2 infection and
388 (n = 38%) as symptomatic according to the definitions
described earlier. Women with lesions not identified by clinicians
as herpetic as well as negative for an interval history of genital
sores (n = 362, 36%) were excluded. By degree of HSV-2 clinical
activity, of 388 symptomatic women 101 (26%) had positive
history of GH but no lesions identified at any of the three study
visits, 125 (32%) presented with genital lesions once (1 lesion-visit
or 1 L-V); 92 (24%) - twice (2 lesion-visits or 2 L-V); and 70 (18%)
had lesions observed at all three visits (3 lesion-visits or 3 L-V).
b) Comparison of demographic, risk and clinical
characteristics by study groups
Table 1 displays distribution of selected baseline characteristics by
main study groups: symptomatic vs. asymptomatic. Overall, symp-
tomatic women were younger than asymptomatic women (median
age 36 years vs. 38 years, p = 0.001). White women tended to be
symptomatic as opposed to their African American counterparts (71%
vs. 57%, p = 0.026). In addition, symptomatic women were more
likely to be on combination antiretroviral therapy (35% vs. 26%,
p = 0.013). However, the biggest difference was observed in the use of
herpes treatment: 19% of symptomatic women vs. 3% of asymptom-
atic women reported use of herpes medications at baseline visit
(p,0.0001). There were no statistically significant differences
observed in HIV risk exposure, number of sexual partners, or
proportion of HSV-1 seropositivity between the groups. Demograph-
ic, risk and clinical characteristics were not significantly different when
explored by subgroups of HSV-2 clinical activity or the frequency of
lesion-visits within the symptomatic cohort.
c) Comparison of HIV disease progression markers by
study groups
Table 2 presents values of HIV markers by the main study
groups as well as by subgroups of HSV-2 clinical activity. A
gradient trend was observed such that the values of HIV markers
became progressively worse as the level of HSV-2 clinical activity
progressively increased from mild symptomatic to severe symp-
tomatic with frequent reactivations. Specifically, symptomatic
Figure 1. Flowchart of study participants and description of exposure groups.
doi:10.1371/journal.pone.0009973.g001
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women with outbreaks of genital lesions at all three visits had more
than 3-fold unfavorable differences in outcome HIV markers
compared to asymptomatic women who had none (p,0.001).
Interestingly, among these symptomatic women only 5 had lesions
identified as herpetic at all three visits but they had the highest
viral load values with median plasma HIV RNA of 490,000
copies/ml (interquartile range [IQR]: 205,000–3,865,000) and
lowest CD4 T cell counts with median CD4+ T cell number of
only 14 (IQR: 4–94).
d) Association between frequency of lesion-visits and the
probability of detectable plasma HIV RNA
Crude GEE analyses demonstrated a 21%, 25% and 50%
increased probability of detectable plasma HIV RNA in women
with lesions at one, two and three visits respectively (Table 3).
Corresponding adjusted estimates were 11%, 13% and 21%
(Table 4, trend p-value = 0.005). Similarly, an 8% to a 32%
increase was observed when Poisson extension of log binomial
regression was carried out to estimate the cumulative effect
of repeated lesion-visits on the probability of detectable plasma
HIV RNA at the last or 3rd study visit (Table 5, trend p-value =
0.004).
e) Association between frequency of lesion-visits and
mean differences in the levels of detectable plasma HIV
RNA and CD4+ T cell levels
In the crude GEE models women with lesions at all three visits
were observed to have up to 0.42 (Table 3) and in adjusted
Table 1. Comparison of demographic, risk and clinical characteristics by study groups.
Characteristic/Study Group Asymptomatic (n=262) Symptomatic (n =388) P
Median age at baseline (IQR), years 38 (33–43) 36 (31–40) 0.001
Median age at 1st sex (IQR), years 15 (13–17) 15 (13–17) 0.459
Race/Ethnicity, n (%) African-American 175 (67%) 228 (59%) 0.026
Latina/Hispanic 53 (20%) 91 (23%)
White 24 (9%) 61 (16%)
Other 10 (4%) 8 (2%)
HIV risk exposure category, n (%) Intravenous drug use 98 (38%) 116 (30%) 0.183
Heterosexual risk 96 (37%) 166 (43%)
Transfusion risk 8 (3%) 17 (4%)
Not known 60 (23%) 89 (23%)
Number of lifetime sexual partners, n (%) 0–1 8 (3%) 11 (3%) 0.428
2–4 44 (17%) 47 (12%)
5–9 42 (16%) 69 (18%)
10–49 85 (33%) 121 (31%)
$50 81 (31%) 138 (36%)
Not known 2 (,1%) 2 (,1%)
HSV-1 seropositive, n (%) 204 (78%) 277 (71%) 0.065
Use of herpes treatment at baseline, n (%) 8 (3%) 74 (19%) ,0.001
Use of antiretroviral therapy at baseline, n (%) None 113 (43%) 128 (33%) 0.013
Mono 82 (31%) 125 (32%)
Combination 67 (26%) 135 (35%)
Note: IQR, interquartile range; P, p-value.
doi:10.1371/journal.pone.0009973.t001
Table 2. Comparison of baseline HIV disease markers by study groups.
Characteristic/Study Group
Asymptomatic
(N=262) Symptomatic (N=388) P*
SR GH{ (N=101) 1 L–V{ (N=125) 2 L–V (N=92) 3 L–V (N=70)
Number/Total (%) with HIV pVL
#4,000 copies/ml
107/258 (41%) 36/99 (36%) 34/125 (27%) 22/88 (25%) 9/69 (13%) ,0.001
Median HIV pVL (IQR), copies/ml** 25,000 (12,000–
100,000)
42,000 (13,000–
1000,000)
46,000 (19,000–
140,000)
76,500 (23,000–
180,000)
92,000 (20,500–
245,000)
,0.001
Median CD4+ T cell count (IQR), cells/mm3 418 (285–593) 391 (270–567) 347 (179–542) 282 (147–430) 138 (19–365) ,0.001
Note: IQR, interquartile range; SR GH, self reported genital herpes; L-V, lesion-visit; {positive self report of genital herpes only; {number of visits with lesions.
* P - p-value for overall comparison of symptomatic group vs. asymptomatic group.
** among women with HIV pVL .4,000 copies/ml.
doi:10.1371/journal.pone.0009973.t002
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models up to 0.29 log10 copies/ml higher mean plasma HIV
RNA levels compared to women in the asymptomatic group who
had no lesion-visits (Table 4, trend p-value ,0.001). The average
difference in CD4+ T cell counts was up to 273 cells less among
women with lesions at all three visits in the crude models
compared to women in asymptomatic group (Table 3) but only
up to 51 cells less in the multivariate models adjusted for baseline
CD4+ T cell count (Table 4, trend p-value ,0.001). This
difference was up to 101 cells less when linear regression was
carried out at the 3rd visit (Table 5, trend p-value ,0.001).
Discussion
Our findings indicate that the levels of HIV replication and
immunocompromise are associated with the presence of active
HSV-2 infection. Specifically, two sides of the observed
association deserve further evaluation: 1) HIV induced CD4+ T
cell loss directly correlated with the degree of HSV-2 activity or
frequent symptomatic HSV-2 reactivations; and 2) active HSV-2
infection with frequent HSV-2 reactivations was, in turn,
associated with modestly elevated plasma HIV RNA levels and
reduced CD4+ T cell count over time, compared to women
remaining clinically asymptomatic after adjusting for baseline
CD4+ T cell levels.
Immunological determinants of HSV-2 infection severity are
not completely understood and there are few data on the
associations between innate/acquired immune responses and
frequencies of HSV-2 reactivation. Moreover, data regarding the
relative importance of CD8+ T cells vs. CD4+ T cells as pure
effector cells in controlling HSV-2 infection remains controversial
[17–21]. The correlation of CD4+ T cell depletion with
frequency/severity of symptomatic recurrences observed in this
study suggests that CD4+ T cells are perhaps one of the
important immunologic correlates of protection against HSV-2
reactivations.
While it appears that T cell mediated immunity is of key
importance in keeping HSV-2 in check, infiltration and
persistence of the same T cells as well as other inflammatory
cells at the site of inflammation may in fact provide a perfect
milieu for HIV to infect additional CD4+ T cells and thus,
enhance HIV replication. Recent in situ study of the cellular
infiltrates of HSV-2 lesions demonstrated that CD4+ T cells
accumulated at the site of lesions had enriched CCR5 expression
and were in close proximity to dendritic cells (DCs) expressing
DC-SIGN or CD123 of DCs, the receptor known for the ability
to transfer HIV to CD4+ T cells [22]. This may present a risk for
enhanced local HIV replication and the potential for its systemic
dissemination, which perhaps depends on the extent and duration
of local inflammation elicited by host immune responses. Indeed,
a modest but consistent trend towards elevated plasma HIV RNA
levels in symptomatic women compared to asymptomatic women
was observed even after adjusting for baseline CD4+ T cell levels.
Table 3. Crude prevalence risk ratios (PRs) of detectable plasma HIV RNA and mean differences in plasma HIV RNA and CD4+ T cell
counts (from the GEE analysis with robust variance estimation) by degree of HSV-2 clinical activity.
Detectable plasma HIV RNA
(.4,000 copies/ml)
Mean difference (D) in log10 plasma
HIV RNA
Mean difference (D) in CD4+ T cell
counts
Grade N Crude PR (95% CI) P Crude mean D (95% CI) P Crude mean D (95% CI) P
Asymptomatic 262 1.0 (reference) 0.00 (reference) 0.00 (reference)
SR GH { 101 1.07 (0.92, 1.25) 0.388 +0.10 (20.05, 0.25) 0.201 246 (2108, 17) 0.150
1 L-V{ 125 1.21 (1.06, 1.38) 0.005 +0.19 (0.05, 0.32) 0.006 295 (2152, 2 37) 0.001
2 L-V 92 1.25 (1.09, 1.44) 0.002 +0.28 (0.12, 0.44) 0.001 2176 (2235, 2116) ,0.001
3 L-V 70 1.50 (1.34, 1.68) ,0.001 +0.42 (0.25, 0.58) ,0.001 2273 (2336, 2212) ,0.001
Note: GEE, Generalized Estimating Equations; CI, confidence interval; PR, prevalence ratio; P, p-value; SR GH, self reported genital herpes; L-V, lesion-visit; {positive self
report of genital herpes only; {number of visits with lesions.
doi:10.1371/journal.pone.0009973.t003
Table 4. Adjusted* prevalence risk ratios (PRs) of detectable plasma HIV RNA and mean differences in plasma HIV RNA and CD4+ T
cell counts (from the GEE analysis with robust variance estimation) by degree of HSV-2 clinical activity.
Detectable plasma HIV RNA
(.4,000 copies/ml)
Mean difference (D) in log10 plasma
HIV RNA
Mean difference (D) in CD4+ T cell
counts
Grade N Adjusted PR (95% CI) P Adjusted mean D (95% CI) P Adjusted mean D (95% CI) P
Asymptomatic 262 1.0 (reference) 0.00 (reference) 0.00 (reference)
SR GH{ 101 1.05 (0.90, 1.22) 0.509 +0.11 (20.03, 0.25) 0.130 25 (223, 13) 0.595
1 L-V{ 125 1.11 (0.98, 1.27) 0.105 +0.15 (0.02, 0.27) 0.026 219 (239, 230) 0.047
2 L-V 92 1.13 (0.98, 1.30) 0.083 +0.16 (0.01, 0.31) 0.034 232 (251, 213) 0.001
3 L-V 70 1.21 (1.06, 1.39) 0.005 +0.29 (0.13, 0.44) ,0.001 251 (281, 221) 0.001
Trend P=0.005 Trend P,0.001 Trend P,0.001
Note: GEE, Generalized Estimating Equations; CI, confidence interval; PR, prevalence ratio; P, p-value; SR GH, self reported genital herpes; L-V, lesion-visit; *adjusted for
baseline CD4+ T cell count, herpes medications and type of antiretroviral therapy used at the visit, age, race, lifetime number of sexual partners, injection and
noninjection drug use; {positive self report of genital herpes only; {number of visits with lesions.
doi:10.1371/journal.pone.0009973.t004
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However, it is possible that these changes may have been due to
incomplete adjustment of immunosuppression by CD4+ T cells.
Despite that, the observed difference of 0.29 log10 copies/ml in
plasma HIV RNA load in women with frequent lesion-visits
compared to women who had none is very similar to the 0.25
log10 reduction in mean plasma HIV RNA observed in the
recent acyclovir suppressive therapy trial [23] which translated
into a 16% reduction in HIV disease progression [24]. The fact
that the acyclovir experimental trial and our observational study
in which most participants did not use acyclovir or other herpes
medications found similar magnitude changes in HIV viral load,
leads us to speculate whether the frequency and severity of HSV-
2 reactivations were responsible for the magnitude of the
observed effect in the trial. It is unlikely that the small to modest
changes in HIV disease markers associated with HSV-2
reactivations observed in this population will negatively affect
the development of AIDS or overall mortality, particularly in the
HAART era. On the other hand, these seemingly small viral load
changes and reductions in disease progression may not be
innocuous. A recent systematic review and meta- analysis of small
viral load changes in treatment naı¨ve HIV positive adults showed
that even small increases in plasma HIV RNA levels can
eventually lead to faster disease progression and a higher risk of
ongoing HIV transmission [25]. Although it is possible that the
reductions in HIV RNA load observed in clinical trials may have
been mediated through the recently discovered inhibitory effect
of acyclovir on HIV reverse transcriptase, this effect was noted to
be dependent on the ability of HSV-2 and other herpesviruses to
provide sufficient amounts of activated acyclovir [26]. This would
likely only be achieved if there is sufficient replication of HSV-2
and of other herpesviruses present in the host at the time.
Multiple other trials observed similar or greater magnitude
reductions in plasma HIV RNA levels with suppressive herpes
therapy [27–30].
The magnitude of CD4+ T cells lost due to frequent
symptomatic HSV-2 reactivations after adjustment for baseline
CD4+ T cell levels was not high and may seem to be negligible.
However, it is possible that the CD4+ T cell values at the lesion-
visits may in fact represent the ‘‘elevated’’ values due to increased
activation of CD4+ and other immune cells in response to HSV-2
reactivation which may exacerbate CD4+ T cell loss. In support of
this possibility is the observation of higher CD4+ T cell counts
among treatment naı¨ve HIV-1/HSV-2 co-infected adults in early
HIV infection [31] which may reflect vigorous immune response
to HSV-2 reactivations in a not yet deeply immunosuppressed
host. Indeed, the trend of CD4+ T cell loss was slight but persisted
across the visits and by the time of the last visit those with lesions at
all three visits had the lowest mean CD4+ T cell counts compared
to those who had none.
A main limitation of the study is the possible misclassification
bias due to use of self reported lesions as one of the indicators for
the presence of active HSV-2 infection. The WIHS women have
not been specifically educated for HSV-2 which can considerably
increase the recognition of mild or atypical symptoms [32,33].
This would be particularly relevant to the asymptomatic group as
subsequent follow up data revealed that nearly 75% (n = 196) of
262 asymptomatic women experienced symptoms suggestive of
HSV-2 reactivation during extended follow up. Thus, the results
of this study are likely to be underestimated as the study did not
use HSV-2 uninfected women as controls in whom the possibility
of clinical and subclinical reactivations should be minimal if not
absent. Another limitation is the absence of laboratory confir-
mation of genital HSV-2 reactivations in these women. However,
laboratory confirmation of HSV-2 reactivations alone is not
optimal as HSV-2 detection is influenced by multiple factors such
as the intermittent nature of HSV-2 shedding, shedding from
multiple anatomic locations as well as the laboratory methodol-
ogy used. Other limitations include the use of semiannual data
that precluded direct assessment of recurrences between the visits
and possibly limited generalizability to those with incident HIV
and HSV-2 infections where viral and host immune response
dynamics are different from those with established infections.
In summary, HIV induced CD4+ T cell loss was associated with
symptomatic and frequent HSV-2 reactivations. Symptomatic
HSV-2 infection with frequent reactivations, in turn, was
associated with modestly elevated HIV replication and reduced
CD4+ T cell count over time. Long term studies will be necessary
to clarify the exact role the frequency and severity of HSV-2
reactivations play in the natural history of HIV infection,
particularly in developing countries where there is no universal
access to HAART therapy. In addition, since HSV-2 is most active
immediately after HSV-2 acquisition it may be worth to
investigate whether early herpes suppressive therapy will delay
the need for initiation of HAART in both developing and
developed country settings among individuals with frequent HSV-
2 reactivations.
Table 5. Adjusted* prevalence risk ratios (PRs) of detectable plasma HIV RNA and mean differences in plasma HIV RNA and CD4+ T
cell counts (from the cross-sectional log binomial and linear regression models at the 3rd visit) by degree of HSV-2 clinical activity.
Detectable plasma HIV RNA
(.4,000 copies/ml)
Mean difference (D) in log10 plasma
HIV RNA
Mean difference (D) in CD4+ T cell
counts
Grade N Adjusted PR (95% CI) P Adjusted mean D (95% CI) P Adjusted mean D (95% CI) P
Asymptomatic 262 1.0 (reference) 0.00 (reference) 0.00 (reference)
SR GH{ 101 1.08 (0.89, 1.30) 0.449 +0.18 (20.006, 0.37) 0.057 213 (250, 23) 0.471
1 L-V{ 125 1.11 (0.94, 1.32) 0.212 +0.19 (0.02, 0.37) 0.028 242 (276, 28) 0.015
2 L-V 92 1.14 (0.96, 1.37) 0.139 +0.21 (0.02, 0.41) 0.029 264 (2103, 226) 0.001
3 L-V 70 1.32 (1.12, 1.56) 0.001 +0.27 (0.07, 0.46) 0.007 2101 (2144, 259) ,0.001
Trend P=0.004 Trend P= 0.004 Trend P=,0.001
Note: CI, confidence interval; PR, prevalence ratio; P, p-value; SR GH, self reported genital herpes; L-V, lesion-visit; *adjusted for baseline CD4+ T cell count, herpes
medications and type of antiretroviral therapy used at the visit, age, race, lifetime number of sexual partners, injection and noninjection drug use; {positive self report of
genital herpes only; {number of visits with lesions.
doi:10.1371/journal.pone.0009973.t005
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